Advertisement
Advertisement
Ideaya Biosciences price target raised to $79 from $74 at JPMorgan
PremiumThe FlyIdeaya Biosciences price target raised to $79 from $74 at JPMorgan
21d ago
Ideaya Biosciences price target raised to $30 from $27 at Goldman Sachs
Premium
The Fly
Ideaya Biosciences price target raised to $30 from $27 at Goldman Sachs
23d ago
Ideaya Biosciences price target raised to $41 from $38 at RBC Capital
Premium
The Fly
Ideaya Biosciences price target raised to $41 from $38 at RBC Capital
23d ago
Ideaya Biosciences reports overall survival data from darovasertib trial
PremiumThe FlyIdeaya Biosciences reports overall survival data from darovasertib trial
25d ago
Promising Potential of IDEAYA Biosciences: Strong Efficacy and Financial Stability Support Buy Rating
Premium
Ratings
Promising Potential of IDEAYA Biosciences: Strong Efficacy and Financial Stability Support Buy Rating
27d ago
IDEAYA Biosciences: Promising Outlook for Darovasertib in Uveal Melanoma Drives Buy Rating
Premium
Ratings
IDEAYA Biosciences: Promising Outlook for Darovasertib in Uveal Melanoma Drives Buy Rating
1M ago
Ideaya Biosciences initiated with a Buy at Guggenheim
PremiumThe FlyIdeaya Biosciences initiated with a Buy at Guggenheim
2M ago
Ideaya Biosciences price target raised to $44 from $43 at Mizuho
Premium
The Fly
Ideaya Biosciences price target raised to $44 from $43 at Mizuho
2M ago
IDEAYA Biosciences: Promising Clinical Developments and Strategic Positioning Highlighted by Buy Rating
Premium
Ratings
IDEAYA Biosciences: Promising Clinical Developments and Strategic Positioning Highlighted by Buy Rating
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100